{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:17:51Z","timestamp":1762157871533,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clgc.2021.03.018","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T03:34:38Z","timestamp":1617420878000},"page":"468.e1-468.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0264","authenticated-orcid":false,"given":"Michael","family":"Szarek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6182-0569","authenticated-orcid":false,"given":"Michael N.","family":"Needle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5095","authenticated-orcid":false,"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.03.018_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"17","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2021.03.018_bib0002","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5062","article-title":"TIVO-3: final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)","volume":"38","author":"Pal","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.018_bib0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40273-018-0752-0","article-title":"Q\u2011TWiST analysis to assess benefit\u2013risk of pembrolizumab in patients with PD\u2011L1\u2013positive advanced or metastatic non\u2011small cell lung cancer","volume":"37","author":"Huang","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clgc.2021.03.018_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.07.008","article-title":"Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial","volume":"84","author":"Marino","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2021.03.018_bib0005","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1185\/03007991003590860","article-title":"Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Sherrill","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clgc.2021.03.018_bib0006","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2012.149","article-title":"Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-\u03b1","volume":"106","author":"Patil","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2021.03.018_bib0007","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203)","volume":"36","author":"Chen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.018_bib0008","article-title":"Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus monotherapy in patients with advanced renal cell carcinoma (RCC)","volume":"38","author":"Lee","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.03.018_bib0009","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clgc.2019.05.010","article-title":"A Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab versus everolimus in advanced renal cell carcinoma (aRCC)","volume":"17","author":"Shah","year":"2019","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:06Z","timestamp":1761564906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1558767321000811"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.018","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}